menu
    • menu
    [{"orgOrder":0,"company":"Nxera Pharma","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Cenerimod","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Nxera Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Nxera Pharma \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Nxera Pharma \/ Viatris"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cenerimod","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cenerimod","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Viatris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Cenerimod","moa":"S1P1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Viatris"}]

    Find Clinical Drug Pipeline Developments & Deals for Cenerimod

    Menu

    Cenerimod

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nxera Pharma

                            Country arrow
                            MAGHREB PHARMA
                            Not Confirmed

                            Nxera Pharma

                            Country arrow
                            MAGHREB PHARMA
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nxera Assigns Cenerimod Japan & APAC Rights to Viatris

                            Details : Under the agreement, Viatris will hold the right of ACT-334441 (cenerimod) for the development and commercialization. It is a clinical-stage candidate evaluated for autoimmune diseases.

                            Product Name : ACT-334441

                            Product Type : Other Small Molecule

                            Upfront Cash : $10.0 million

                            February 27, 2025

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Idorsia and Viatris Update their Collaboration for Selatogrel and Cenerimod

                            Details : The collaboration aims for the global development and commercialization rights to ACT-246475 (selatogrel), a reversible, and selective 2-phenylprimdine-4-carboxamide and ACT-334441 (cenerimod).

                            Product Name : ACT-334441

                            Product Type : Other Small Molecule

                            Upfront Cash : $350.0 million

                            February 26, 2025

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Viatris

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idorsia Initiates OPUS a Phase 3 Program to Investigate Cenerimod for The Treatment of Patients with Systemic ...

                            Details : ACT-334441 (cenerimod), is a highly selective S1P1 receptor modulator, being investigated as an oral once-daily tablet. Cenerimod potentially offers a novel approach for the treatment of SLE, a disease with a significant impact on patients and limited tr...

                            Product Name : ACT-334441

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Cophex
                            Not Confirmed

                            Idorsia Pharmaceuticals

                            Switzerland arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Idorsia to Advance Cenerimod Into Phase 3 Development for Treatment of Patients with Systemic Lupus Erythemato...

                            Details : Cenerimod 4 mg showed clinically meaningful improvement in mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect seen on biological activity. Cenerimod, novel S1P1 receptor modulator an oral treatment of systemic...

                            Product Name : ACT-334441

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 11, 2021

                            Lead Product(s) : Cenerimod

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth